Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer who have progressed on or after platinum-based chemotherapy. The MHLW approval was supported by the Phase 3 LUNAR trial.
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields or TTFields, which are delivered through non-invasive, wearable arrays.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.